This is normal dose escalation response
Researchers found that people prescribed semaglutide, the active ingredient in Wegovy, were 50% more likely to be diagnosed with a hair-loss condition compared to those taking another weight management drug called Contrave (bupropion-naltrexone)
#thefdalawblog #FDA #OPDP #ADPROMO To view or add a comment, sign in Earlier this week, the White House issued a Presidential Memorandum directing the HHS and FDA to address what it characterized as misleading DTC prescription drug advertisements
Neuronal Glud1 (glutamate dehydrogenase 1) over-expressing mice: increased glutamate formation and synaptic release, loss of synaptic activity, and adaptive changes in genomic expression
If someone is actively restricting intake beyond what the medication is already doing, they may experience symptoms like irritability or mood swings
And it is worth addressing directly